Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Influence of Habitual Protein Intake on AA Tracer Oxidation (HPI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03845569
Recruitment Status : Completed
First Posted : February 19, 2019
Last Update Posted : February 19, 2019
Sponsor:
Information provided by (Responsible Party):
Daniel Moore, University of Toronto

Brief Summary:
Protein is an essential nutrient that one's diet to maintain important bodily functions and to recover from exercise. Currently, the Indicator Amino Acid Oxidation method (IAAO) has been used to determine protein requirements in a variety of populations including children, neonates, the elderly and recently, resistance trained populations. This study serves to test the robustness of the IAAO method and to determine if high habitual dietary protein intake, as seen in resistance trained males, has the potential to influence the protein requirements determined by the IAAO method. Further, the current study also aims to determine how the body metabolizes or uses dietary protein and how it might change when consuming a protein intake that is less than what is habitually consumed.

Condition or disease Intervention/treatment Phase
Protein/Amino Acid Metabolism Indicator Amino Acid Oxidation Method Other: Dietary protein intake reduction Other: Three day Controlled Diet Not Applicable

Detailed Description:

This study employed a two-phase randomized crossover design, where participants performed both a High/Habitual protein phase and a moderate protein phase. The Habitual protein phase is designed to model resistance trained individual's habitual protein consumption by providing 2.2g/kg/d in a controlled diet. The Moderate protein phase is designed to investigate the impact of decreasing dietary protein intake to a moderate amount (1.2g/kg/d) over five days on protein metabolism. Both phases used the stable isotope L-[1-13C]Phenylalanine and metabolic trails were modelled after the indicator amino acid oxidation (IAAO) technique.

High Protein Phase The high protein phase is three days in length, with diet-controlled throughout, and a metabolic trail on day 3. Participants will perform whole-body resistance exercise on days one and three.

Moderate protein phase The Moderate protein phase is seven days in length, with MT on days three, five and seven. Dietary intake will be controlled throughout the whole phase providing either 2.2 g/kg/d of protein (days one and two), or 1.2 g/kg/d (days three through seven). Full body resistance exercise will be performed performed on days one, three, five and seven.

This phase will allow measurement of protein metabolism over five days following a decrease in dietary protein intake, and to determine the effect of dietary changes on the IAAO method.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 5 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: Randomized crossover trial.
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Impact of Habitual Protein Intake on Estimates of Dietary Protein Requirements in Resistance Trained Athletes
Actual Study Start Date : November 1, 2017
Actual Primary Completion Date : April 18, 2018
Actual Study Completion Date : April 18, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dietary Proteins

Arm Intervention/treatment
Habitual Protein phase
A trial investigating protein oxidation/metabolism that was used to model resistance trained individual's habitual dietary protein intake (2.2g/kg/d).
Other: Three day Controlled Diet
Three days of a controlled diet providing 2.2g/kg/d of dietary protein with protein metabolism measured on day 3. This was used to model the habitual intake of this cohort.

Experimental: Moderate Protein Phase
A series of three trials over a one week period investigating protein oxidation/metabolism that was used to investigate the metabolic response of decreased protein intake (1.2g/kg/d) over a period of five days (trials on days 1, 3, 5 following reduction in protein intake from 2.2g/kg/d to 1.2g/kg/d) relative to the Habitual protein phase trial.
Other: Dietary protein intake reduction
Following two days of controlled diet at 2.2g/kg/d of dietary protein, intake was reduced to 1.2g/kg/d for five days, and protein metabolism was measured on days 1, 3, and 5.




Primary Outcome Measures :
  1. Phenylalanine excretion (F13CO2) [ Time Frame: Through study completion, an average of 3 months ]
    Expressed as µmol/kg/h; phenylalanine excretion is determined via breath enrichment (F13CO2) of the oral tracer. Breath 13CO2 enrichment was measured by continuous-flow isotope ratio mass spectrometry

  2. Phenylalanine oxidation (PheOX) [ Time Frame: Through study completion, an average of 3 months ]
    Expressed as µmol/kg/h; phenylalanine excretion is determined via breath and urine enrichment of the oral tracer. Breath 13CO2 enrichment was measured by continuous-flow isotope ratio mass spectrometry and urinary L-[1-13C] phenylalanine was measured by liquid chromatography tandem mass spectrometry


Secondary Outcome Measures :
  1. Phenylalanine Rate of Appearance (PheRa/Flux) [ Time Frame: Through study completion, an average of 3 months ]
    In µmol/kg/h; phenylalanine rate of appearance is determined via urinary enrichment of the oral tracer by liquid chromatography tandem mass spectrometry.

  2. Net Protein Balance [ Time Frame: Through study completion, an average of 3 months ]
    In µmol/kg/h; calculated as the difference between whole-body protein synthesis and protein breakdown. ). Breath 13CO2 enrichment was measured by continuous-flow isotope ratio mass spectrometry and urinary L-[1-13C] phenylalanine was measured by liquid chromatography tandem mass spectrometry.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy, weight-trained individuals that have trained consistently for > 1 year
  • Habitually dietary protein consumption of 1.9 to 3.0g/kg/d
  • Train each muscle group (i.e. chest, back, legs) at least twice a week
  • Body mass stable in the last month
  • Meets strength relative-to-weight guidelines (adapted from Morton et al., 2016; Chilibeck et -al., 1997)

    • Bench Press: - Bodyweight (kg) * 1.25
    • Leg Press: - Bodyweight (kg) *4.0

Exclusion Criteria:

  • Inability to meet health and PA guidelines according to the PAR-Q+
  • Inability to adhere to any of the protocol guidelines (e.g. alcohol and caffeine consumption)
  • Regular tobacco use, screened by questionnaire
  • Illicit drug use (e.g. growth hormone, testosterone, etc.), screened by a survey in training log

    • 1 month sedentary in the last 6 months prior to study participation
    • 30 minutes of continuous cardio per exercise session
  • BMI > or equal to 35
  • Individual plans to increase or decrease body mass in the next 3 months
  • Use of supplements (excluding whey protein), such as creatine and beta-alanine, in the last 30 days

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03845569


Locations
Layout table for location information
Canada, Ontario
Goldring Centre for High Performance Sport
Toronto, Ontario, Canada, M5S 2C9
Sponsors and Collaborators
University of Toronto
Investigators
Layout table for investigator information
Principal Investigator: Daniel R Moore, PhD University of Toronto
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Daniel Moore, Principle Investigator, University of Toronto
ClinicalTrials.gov Identifier: NCT03845569    
Other Study ID Numbers: HPI
First Posted: February 19, 2019    Key Record Dates
Last Update Posted: February 19, 2019
Last Verified: February 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Daniel Moore, University of Toronto:
Amino acids
Protein
metabolism
IAAO
Tracer
Indicator amino acid
Resistance trained